Diagnosis and management of endometrial hyperplasia

Current Obstetrics and Gynaecology

Volumn 7, Issue 1, 1997, Pages 8-15

  Oram, D H ^a   Jeyarajah, A R ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; GOSERELIN; PROGESTERONE; TAMOXIFEN;

DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG EFFICACY; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; ULTRASOUND;

EID: 0030915183     PISSN: 09575847     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-5847(97)80004-2     Document Type: Conference Paper

References (6)

1. Cavanagh D, Marsden DE, Ruffolo EH. Carcinoma of the endometrium. Obstetrics & Gynecology Annual 1984; 13: 211-260
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 1985; 56: 403-412
3. Gordon MD, Ireland K. Pathology of hyperplasia and carcinoma of the endometrium. Seminars in Oncology 1994; 21:64-70
4. Deligdisch L, Cohen CJ. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985; 56: 1452-1455
5. Deligdisch L, Holinka CF. Progesterone receptors in two groups of endometrial carcinoma. Cancer 1986; 57: 1385-1388
6. Hunter JE, Tritz DE, Howell MG et al. The prognostic and therapeutic implications of cytologic atypia in patients with endometrial hyperplasia. Gynecol Oncol 1994; 55: 66-71